4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Crescent Biopharma, Inc. (CBIO) operates in the Biotechnology industry and is headquartered in Waltham, United States with about 55 employees. Its market capitalization is roughly $422 million. In the fiscal year ended 2025-12-31, CBIO reported $11M in revenue and ($154M) in net income.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Interactive charts & full statements → Open the CBIO valuation workbench →
| Income statement | 2025-12-31 |
|---|---|
| Total Revenue | $11M |
| Operating Income (EBIT) | ($153M) |
| Net Income | ($154M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $1M | $11M | $0M | $0M | $0M | — |
| Operating Income (EBIT) | ($25M) | ($92M) | ($26M) | ($21M) | ($14M) | — |
| Net Income | ($23M) | ($92M) | ($25M) | ($22M) | ($15M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total Assets | $240M | $36M |
| Total Liabilities | $37M | $51M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CBIO viewer.
About TickerBase · Data methodology & sources